Archive for the ‘research’ Category

Alan MacDonald, MD: The Connection Between Syphilis, Lyme & Dementia

https://rumble.com/v2xnzl8-alan-macdonald-md-the-connection-between-syphilis-lyme-and-dementia.html  Video Here (Approx. 1 hour 15 min)

Alan MacDonald, MD, The Connection Between Syphilis, Lyme, & Dementia

Source: Lillian McDermott Radio Show/Classroom
https://www.bitchute.com/video/3faoq7wH7Mw0/

June, 2023

A pathologist’s job is to identify the cause of death of an individual. For Alan MacDonald, MD, his journey has led him to discover more than any of us could have imagined. Because this is the first time in 11 years that we have had a pathologist in The Classroom, I will just say, I am grateful to Dr. MacDonald for sharing the connection between syphilis, Lyme, and dementia, in The Classroom!

For more:

Paralyzed by Lyme, They Were Helped With Combo Treatments

https://www.lymedisease.org/remission-from-lyme-paralysis/

Paralyzed by Lyme, they were helped with combo treatments

By Lonnie Marcum

July 19, 2023

A new study from France looks at the use of combination antibiotics and anti-parasitic treatments in patients with limb paralysis as a result of tick-borne infections, including Lyme disease.

Approximately 70% of the patients in this study showed complete remission of symptoms after long-term treatment—a statistic that lines up with the MyLymeData treatment study.

The paper entitled, Complete Remission in Paralytic Late Tick-Borne Neurological Disease Comprising Mixed Involvement of Borrelia, Babesia, Anaplasma, and Bartonella: Use of Long-Term Treatments with Antibiotics and Antiparasitics in a Series of 10 Cases was published in Antibiotics.

The inclusion criteria for this study required a score of 4 or more on the Kurtzke EDSS disability scale; positive blood tests for one or more tick-borne pathogen (including Borrelia burgdorferi, Babesia, Anaplasma or Bartonella); and chronic general symptoms including fatigue, pain, and cognitive deficits lasting six or more months.

The Extended Disability Status Scale (EDSSis a tool commonly used to quantify the level of disability in patients with multiple sclerosis. The EDSS grades six bodily functions, including visual, brain, bowel/bladder and sensory functions, as well as the patients’ ability to walk and take care of themselves.

All 10 of the patients that qualified for this study were severely disabled with partial or complete paralysis in at least one limb. Five of the 10 required a wheelchair for mobility, and four required assistive devices like walking sticks to get around.

Complete remission for 7 out of 10

Following extended treatment, seven out of 10 patients (70%) showed complete remission of symptoms. Among the nine patients with positive Borrelia serology (along with co-infections), 77% obtained complete remission.

The treatment administered varied according to the patient’s infection profile. The majority of the patients received repeated oral regimens of azithromycin-doxycycline and azithromycin-doxycycline-rifampin plus a minimum of three 35-day cycles of IV ceftriaxone. The eight patients co-infected with Babesia (a parasite) were also administered anti-parasitic cycles of atovaquone–azithromycin. The mean duration of treatment was 20 months +/- 6 months. (Trouillas 2023)

Historically, patients with late-stage Lyme disease have poor outcomes to single regimens of 10-day IV ceftriaxone. (I’ve previously written about brain inflammation, and small fiber neuropathy found in patients with continuing symptoms after short-term treatment for Lyme disease.)

And we have decades of strong evidence that under-treatment with single antibiotics is consistent with persistent infection in animal studies. (Embers 2012)

Two weeks isn’t enough

As far back as 1990, Dr. Allen Steere co-authored a paper on patients with persistent late-stage neurological Lyme disease.

In this paper Dr. Steere and his co-authors state:

Months to years after the initial infection with B. burgdorferi, patients with Lyme disease may have chronic encephalopathy, polyneuropathy, or less commonly, leukoencephalitis. These chronic neurologic abnormalities usually improve with antibiotic therapy.

Six months after a two-week course of intravenous ceftriaxone (2 g daily), 17 patients (63 percent) had improvement, 6 (22 percent) had improvement but then relapsed, and 4 (15 percent) had no change in their condition.

Six months after treatment, more than one third of the patients either had relapsed or were no better. In addition, more than half had previously received antibiotic therapy thought to be appropriate for their stage of disease and still had progression of the illness. The likely reason for relapse is failure to eradicate the spirochete completely with a two-week course of intravenous ceftriaxone therapy. (Logigian 1990)

MyLymeData

In fact, the MyLymeData study validates that longer antibiotic treatment durationare associated with moderate to a very great deal of improvement. (Johnson 2020)

MyLymeData is currently the largest observational study of patients using real-world data to analyze the response to treatment of chronic Lyme disease patients. The majority of patients (57%) reported treatment durations of four or more months,

The results of this new French study demonstrate the importance of clinicians being able to continue treatment until a patient’s symptoms have resolved. It is clear, at least in this study, that the presence of co-infections greatly compounds one’s disease progress and treatment options.

LymeSci is written by Lonnie Marcum, a Licensed Physical Therapist and mother of a daughter with Lyme. She served two terms on a subcommittee of the federal Tick-Borne Disease Working Group. Follow her on Twitter: @LonnieRhea  Email her at: lmarcum@lymedisease.org.

References

Embers ME, Barthold SW, Borda JT, Bowers L, Doyle L, Hodzic E, et al. Persistence of Borrelia burgdorferi in Rhesus Macaques following Antibiotic Treatment of Disseminated Infection. PLoS ONE. 2012;7(1):e29914. Available at: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0029914.

 Johnson, L.; Shapiro, M.; Stricker, R.B.; Vendrow, J.; Haddock, J.; Needell, D. Antibiotic Treatment Response in Chronic Lyme Disease: Why Do Some Patients Improve While Others Do Not? Healthcare 2020, 8, 383. https://www.mdpi.com/2227-9032/8/4/383

Logigian EL, Kaplan RF, Steere AC. Chronic neurologic manifestations of Lyme disease. N Engl J Med. 1990 Nov 22;323(21):1438-44. doi: 10.1056/NEJM199011223232102. PMID: 2172819.

Trouillas P, Franck M. Complete Remission in Paralytic Late Tick-Borne Neurological Disease Comprising Mixed Involvement of Borrelia, Babesia, Anaplasma, and Bartonella: Use of Long-Term Treatments with Antibiotics and Antiparasitics in a Series of 10 Cases. Antibiotics. 2023; 12(6):1021. https://doi.org/10.3390/antibiotics12061021

_________________

For more:

Lyme Disease & the Pursuit of a Clinical Cure

https://www.frontiersin.org/articles/10.3389/fmed.2023.1183344/full

REVIEW article

Front. Med., 24 May 2023
Sec. Infectious Diseases: Pathogenesis and Therapy
Volume 10 – 2023 | https://doi.org/10.3389/fmed.2023.1183344

Lyme disease and the pursuit of a clinical cure

  • Division of Immunology, Tulane National Primate Research Center, Tulane University Health Sciences, Covington, LA, United States

Lyme disease, caused by the spirochete Borrelia burgdorferi, is the most common vector-borne illness in the United States. Many aspects of the disease are still topics of controversy within the scientific and medical communities. One particular point of debate is the etiology behind antibiotic treatment failure of a significant portion (10–30%) of Lyme disease patients. The condition in which patients with Lyme disease continue to experience a variety of symptoms months to years after the recommended antibiotic treatment is most recently referred to in the literature as post treatment Lyme disease syndrome (PTLDS) or just simply post treatment Lyme disease (PTLD). The most commonly proposed mechanisms behind treatment failure include host autoimmune responses, long-term sequelae from the initial Borrelia infection, and persistence of the spirochete. The aims of this review will focus on the in vitro, in vivo, and clinical evidence that either validates or challenges these mechanisms, particularly with regard to the role of the immune response in disease and resolution of the infection. Next generation treatments and research into identifying biomarkers to predict treatment responses and outcomes for Lyme disease patients are also discussed. It is essential that definitions and guidelines for Lyme disease evolve with the research to translate diagnostic and therapeutic advances to patient care.

_________________

Translation:  TIME FOR CHANGE!

Thankfully the study authors point out the following:
  • Without intervention, Bb establishes a persistent/chronic infection in both its reservoir and non-reservoir hosts.  
  • Controversy regarding chronic infection revolves around whether Bb can persist after antibiotics and whether they are capable of causing the symptoms patients experience.
  • There are many bacterial species associated with persistent infections in humans including: Mycobacterium tuberculosisPseudomonas aeruginosaEscherichia coliStaphylococcus aureus, and B. burgdorferi (109).
  • Bacterial tolerance is different from resistance in that bacteria are not actively growing in the presence of the antibiotic and there is no heritable genetic change in the persistent bacteria’s genome (110111).
  • The stress response and other mechanisms allow bacteria, including Borrelia, to survive lethal conditions such as limited nutrients, extreme pH levels, and the presence of certain antibiotics.
  • Drug-induced bacterial persisters show a biphasic killing curve and the regrown persister cells have the same minimum inhibitory concentration (MIC) to the administered antibiotic as the original population but a higher minimum bactericidal concentration (MBC) (112).
  • Several independent studies have demonstrated that Bb can form drug-tolerant persister cell in vitro.
  • In vivo studies of Bb antibiotic persistence often use different parameters that can make comparisons between two or more studies difficult.
  • It is likely that lack of consensus of definitions and diagnosis lead to the treatment controversy.
  • Despite treatment controversy, a biostatistical review of the literature found that retreatment of LD with antibiotics may be beneficial in certain cases (163).
  • Since research for PTLD revolves around autoimmunity, immune-mediated factors, and/or persistent infection, most drugs fit into one of three categories: immune therapies, pathogen specific inhibitors, or antibiotics.
  • Studies screening drug libraries have revealed:
    • disulfiram has demonstrated borreliacidal activity both in vitro and in vivo (174176)
    • vancomycin may have efficacy against stationary Bb based upon cultures and evaluation in SCID mice (177)
    • hygromycin A has shown efficacy against Bb, without disturbing the gut microbiome like so many broad-spectrum antibiotics, in vitro and in an in vivo mouse assay, but it’s use in preventing persistent infections was not determined (178)
    • drug combinations such as daptomycin or artemisinin, cefoperazone, and doxycycline as well as the combination sulfachlorpyridazine, daptomycin, and doxycycline have shown evidence of in vitro activity against Bb persisters and round bodied forms (117172). Azlocillin and cefotaxime are effective in in vitro killing against Bb persisters induced by doxycycline, which appear to be more tolerant to other antibiotics (179).
    • daptomycin or daunomycin, doxycycline, and cefuroxime have had success in sterilizing in vitro Bb biofilm-like microcolonies (180181).
    • dapsone, used in treatment of leprosy, has had success when combined with other antibiotics in killing biofilm-like Bb (182), and dapsone has had positive effects in a small PTLD and co-infection clinical study (183).
    • oregano, cinnamon bark, clove, and various flowers, grasses, and berries, as well as natural compounds such as those found in bee venom and its component melittin have demonstrated potential in vitro growth inhibition against Bb and its various forms (184188) but need further research to determine the safety and efficacy of, and the composition and activity of the exact compounds found.
  • Curative treatment during early LD stages is a key to solving the current PTLD public health problem.
  • It is likely that more than one mechanism is involved in antibiotic treatment failure that leads to PTLD.
  • The current treatment guidelines are dependent upon the immune system’s ability to clear persistent spirochetes and conditional to the surviving spirochetes being non-viable and not enough to sustain a prolonged immune response.
  • In order to make PTLD a thing of the past, personalized medicine is required as well as the need to evolve and progress with scientific discoveries and innovations.  

Powassan Virus Persistence After Acute Infection

https://journals.asm.org/doi/10.1128/mbio.00712-23

Powassan virus persistence after acute infection

Authors
6/20/23
Survivors of Powassan encephalitis often have persistent neurological disease. A new mouse model replicates some elements of the human disease and demonstrates the presence of viral RNA in the brain as well as myelitis more than 2 mo after the acute infection. The related tick-borne encephalitis and West Nile Neuroinvasive Disease (WNND) also have common neurological sequelae, and models for these better-studied diseases provide evidence for prolonged virus, RNA, and inflammation in some cases, in addition to damage from the acute encephalitic disease. A better understanding of the biological basis for persistent signs and symptoms after Powassan encephalitis, currently a rare disease, could benefit from further studies of the more prevalent flaviviral encephalitides.
________________
**Comment**
Unfortunately, the acknowledgment of this will be for a future lucrative vaccine – not treatments or things that will actually help patients.

Please note that Wisconsin is a hot-spot for Powassan.  Read this article on how Powassan IS NOT RARE, yet the CDC continues to state it is.

For more:

Study Says Opioids No Better Than Placebos For Back & Neck Pain

https://www.paintreatmentdirectory.com/posts/opioids-no-better-than-placebos-for-back-and-neck-pain-new-study-says

Opioids No Better Than Placebos For Back and Neck Pain, New Study Says

7/10/23

A new study just published in The Lancet, a highly respected mainstream journal, reported that patients with low back pain and neck pain who were prescribed opioids did no better than patients given a placebo. The randomized, controlled study of 347 patients found that there was no significant difference in pain scores between the two groups at six weeks. A year later, the placebo group had slightly lower pain scores,1.81 compared to 2.37 for the opioid group. The average age of participants in the study was 44.7 years and they all had lower back pain, neck pain or both for 12 weeks or less.

According to the National Institute for Drug Abuse (NIDA), 10-12% of those prescribed opioids develop an addiction. Despite the fact that over a million Americans have died of opioid overdoses to date, opioids continue to be widely prescribed as noted by the CDC. After peaking in 2012 at 81.3 prescriptions per 100 persons nationwide, the prescription opioid rate was 43.3 per 100 persons in 2020. However, some counties had rates that were nine times higher than that. This study indicates that many pain patients are being unnecessarily exposed to devastating and potentially fatal risks for absolutely no benefit.

I believe that the reason that opioids continue to be so widely prescribed despite the risks is that healthcare providers and patients have heard so often that “opioids are the best treatment we have for pain”. This statement has been repeated so often by pharmaceutical interests and their enablers despite the lack of evidence that most people believe it. Will this study be enough to change these beliefs? I doubt it.

Besides patients’ and healthcare providers’ frequently reinforced beliefs that “opioids are the best treatment we have for pain”, there are several other barriers that get in the way of change. These include:

Healthcare providers are not educated about safer and more effective alternatives.

One survey of medical school curriculum in the U.S. found that physicians were receiving less than two hours of education about pain during their four years of medical school. Post-graduate education is largely sponsored by the drug companies, who fund the medical journals through advertising, sponsor most of the continuing education courses and conferences that physicians attend and send sales reps to physicians’ offices to peddle their wares on an almost daily basis. There are no comparable platforms for educating physicians about alternatives to pharmaceuticals for the treatment of pain.

Insurance companies won’t pay for alternative treatments or severely underfund them.

They do not pay for acupuncture, biofeedback, massage, nutritional counseling or supplements, exercise programs, herbal treatments, light therapy or other proven pain treatments. They have not raised fees for chiropractors, mental health providers or physical therapists in over 40 years.

Government policy often blocks access to alternative treatments.

Marijuana is still federally illegal, making it inaccessible for many. The FDA has gone to great lengths to try to ban kratom, a very effective southeast Asian pain-relieving herb, and failing that, has done their best to demonize it. Several states have banned kratom. 

The FDA has also recently declared homeopathy illegal, classifying all remedies as unapproved drugs, despite significant evidence that homeopathy is safe and effective and a long tradition of its use being legal.

No federal or state laws require insurance coverage for most alternatives or adequate fees for the treatments, like physical therapy, psychotherapy and chiropractic, that are covered.

Sign My Petition to Require Insurance Companies to Pay for Alternative Treatments

The supply of alternative service providers cannot currently meet increased demand.

For instance, while the demand for chiropractic services has been increasing, the U.S. Small Business Administration reports that the five-year survival rate of chiropractic practices is only 48.9%. This is most likely due to low fees and excessive paperwork demands by insurance companies.

The physical therapy profession is currently hemorrhaging providers despite increasing demand, with over 22.000 physical therapists leaving the workforce in the last quarter of 2021 alone. Over 15,000 licensed clinical social workers left the workforce during the same time period in professions where there were already significant shortages.

There are already shortages of massage therapists and demand for acupuncturists is already increasing compared to supply. These shortages will be even more severe if insurance coverage is made available.

Find the Right Provider

The Placebo Effect and Chronic Pain

The placebo effect refers to the improvement in a patient’s condition, despite receiving a treatment with no active pharmacological properties, for example: a sugar pill. Research has consistently shown that when patients genuinely believe they are receiving an effective treatment, their bodies often respond accordingly, producing measurable improvements.

The power of placebos extends beyond a mere psychological response; it can lead to actual physiological changes in the body. Studies have shown that the placebo effect can trigger the release of endorphins (the body’s natural opioids), dopamine (the body’s natural mood elevators) and other neurotransmitters associated with pain relief and improved mood. This indicates that the mind possesses an innate ability to activate the body’s self-healing mechanisms.

Placebo-controlled clinical trials are now standard practice in drug development, enabling researchers to evaluate the true effectiveness of new medications, or in the case of the above-described study, older medications.

While placebos have the potential to produce positive outcomes, some have raised ethical concerns about their use. They claim that deceiving patients by prescribing placebos without their knowledge undermines the principle of informed consent. However, I would counter that by pointing out that prescribing potentially dangerous drugs without warning patients of the full range of risks or the fact that a safer alternative exists is a much higher order ethical violation.

Researchers are exploring ethical ways to use placebos. Some studies have shown that even if you tell patients they are getting a placebo for their condition, it still seems to have the desired effect.

Placebos and the Power of the Mind/Body Connection

Placebos are an indicator of the power of the mind-body connection to influence our well-being. The effectiveness of placebos in pain management has been observed for both acute and chronic pain. Placebos have shown significant analgesic effects in conditions such as migraines, osteoarthritis, and even post-surgical pain. They have been proven to reduce pain intensity, increase pain tolerance, and enhance overall well-being. Placebos have also been shown to reduce anxiety and depression and to improve sleep.

Want to try a placebo for yourself or a loved one? Here is a placebo you can order on Amazon:

Conclusion

Many safer treatments for back pain, neck pain and other types of pain exist and should be offered to patients instead of misinforming patients that “opioids are the best treatment we have for pain”. A “best” treatment doesn’t have the potential to kill people.

Cindy Perlin is a Licensed Clinical Social Worker, certified biofeedback practitioner, chronic pain survivor, the author of The Truth About Chronic Pain Treatments: The Best and Worst Strategies for Becoming Pain Free and the founder and CEO of the Alternative Pain Treatment Directory. She has been helping her clients in the Albany, NY area reach their health and wellness goals for over 30 years. She also provides virtual pain consults. See her provider profile HERE

For more:

BTW, in the effort of staying real: The Lancet and other journals have been caught numerous times publishing fraudulent studies and pushing politics rather than science: